Europäische Union - Deutsch - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Europäische Union - Deutsch - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - abirateronacetat - prostata-neoplasmen - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - abirateroni acetas - filmtabletten - abirateroni acetas 250 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 30, cellulosum microcristallinum, lactosum monohydricum 34 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, pro compresso obducto corresp. natrium 5.31 mg. - prostatakarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - abirateroni acetas - filmtabletten - abirateroni acetas 500 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 30, cellulosum microcristallinum, lactosum monohydricum 68 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 10.62 mg. - prostatakarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - abirateronum - filmtabletten - abirateroni acetas 250.00 mg corresp. abirateronum 223 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 30, cellulosum microcristallinum, lactosum monohydricum 34.00 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, pro compresso obducto corresp. natrium 5.3 mg. - prostatakarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - abirateronum - filmtabletten - abirateroni acetas 500.00 mg corresp. abirateronum 446 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 30, cellulosum microcristallinum, lactosum monohydricum 68.00 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 10.6 mg. - prostatakarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - abirateronum - filmtabletten - abirateroni acetas 500 mg corresp. abirateronum 446 mg, lactosum monohydricum 253.2 mg, cellulosum microcristallinum, carmellosum natricum conexum, hypromellosum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (rubrum), e 172 (nigrum) pro compresso obducto corresp. natrium 12.24 mg. - prostatakarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - abirateroni acetas - filmtabletten - abirateroni acetas 1000 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 30, cellulosum microcristallinum, lactosum monohydricum 136 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, pro compresso obducto corresp., natrium 15.92 mg. - prostatakarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - abirateronum - filmtabletten - abirateroni acetas 500 mg corresp. abirateronum 446.0 mg, lactosum monohydricum 90 mg, natrii laurilsulfas, carmellosum natricum conexum, cellulosum microcristallinum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (flavum), pro compresso obducto corresp. natrium 9.96 mg. - prostatakarzinom - synthetika